Overall, these data were confirmed by the PROfound trial, a large phase III trial evaluating the efficacy of Olaparib in HRD mCRPC, whereas 27.9% of the 2792 successfully sequenced tumor specimens were found HR defective, confirming BRCA2, CDK12, and ATM as the three most frequent altered genes (harbored by 33.3, 23, and 22.2% of all the randomized patients, respectively) [54]. This evidence concerns the gene CDK12 and neoplasm.